Skip to main content

Brainsway Ltd. (BWAY)

NASDAQ: BWAY · IEX Real-Time Price · USD
7.69
-0.31 (-3.88%)
After-hours:Sep 17, 2021 4:37 PM EDT
8.00
0.22 (2.83%)
At close: Sep 17, 4:00 PM
Market Cap136.68M
Revenue (ttm)22.06M
Net Income (ttm)-5.39M
Shares Out16.45M
EPS (ttm)-0.36
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume24,801
Open7.71
Previous Close7.78
Day's Range7.57 - 8.12
52-Week Range5.55 - 11.77
Beta0.76
AnalystsStrong Buy
Price Target11.19 (+39.8%)
Est. Earnings DateNov 17, 2021

About BWAY

Brainsway Ltd., a commercial stage medical device company, focuses on the development and sale of non-invasive neuromodulation products in Israel and internationally. It offers deep transcranial magnetic stimulation technology for the treatment of major depressive disorders, obsessive-compulsive disorders, bipolar disorders, post traumatic stress disorders, schizophrenia, smoking cessation, Alzheimer's disease, Asperger syndromes, alcohol addictions, attention deficit hyperactivity disorders, Parkinson's disease, and chronic neuropathic pains t...

IndustryHealth Care Equipment & Supplies
IPO DateApr 17, 2019
Employees100
Stock ExchangeNASDAQ
Ticker SymbolBWAY
Full Company Profile

Financial Performance

In 2020, Brainsway's revenue was $22.06 million, a decrease of -4.52% compared to the previous year's $23.10 million. Losses were -$5.39 million, -47.86% less than in 2019.

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for Brainsway stock is "Strong Buy." The 12-month stock price forecast is 11.19, which is an increase of 39.84% from the latest price.

Price Target
$11.19
(39.84% upside)
Analyst Consensus: Strong Buy

News

BrainsWay to Participate in Two Upcoming Investor Conferences

BURLINGTON, Mass. and JERUSALEM, Sept. 09, 2021 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatmen...

1 week ago - GlobeNewsWire

BrainsWay to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

BURLINGTON, Mass. and JERUSALEM, Aug. 30, 2021 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatment...

2 weeks ago - GlobeNewsWire

BrainsWay Stock Gains On FDA Expanded Use Approval For Its Stimulation Device

The FDA has cleared BrainsWay Ltd's (NASDAQ:BWAY) Deep Transcranial Magnetic Stimulation (Deep TMS) System to reduce comorbid anxiety symptoms in adult patients with depression, also known as anxious de...

4 weeks ago - Benzinga

FDA Clears BrainsWay Deep TMS™ System for Decreasing Anxiety Symptoms in Depressed Patients

Expanded Depression Indication Further Demonstrates Company's Leadership Position Expanded Depression Indication Further Demonstrates Company's Leadership Position

4 weeks ago - GlobeNewsWire

BrainsWay Hosting Key Opinion Leader Webinar on its Deep TMS™ Therapy for Treating Mental Health Disorders

BURLINGTON, Mass. and JERUSALEM, Aug. 17, 2021 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatment...

1 month ago - GlobeNewsWire

BrainsWay Reports Second Quarter 2021 Financial Results and Operational Highlights

Strong Revenue Growth of 45% Year-over-Year in Q2 2021

1 month ago - GlobeNewsWire

BrainsWay to Report Second Quarter 2021 Financial Results on August 11, 2021

CRESSKILL, N.J. and JERUSALEM, July 28, 2021 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments ...

1 month ago - GlobeNewsWire

MindPath Care Centers Hosts Open House in Charlotte to Introduce FDA-Cleared Deep TMS™ Treatment for Major Depressive...

Engaging event for local mental health clinicians to learn more about BrainsWay's Deep Transcranial Magnetic Stimulation (Deep TMS) helmet, cleared to treat MDD and OCD, currently available in Charlotte.

2 months ago - GlobeNewsWire

BrainsWay to Present at Clinical TMS Society Annual Meeting and Psych Congress Elevate

CRESSKILL, N.J. and JERUSALEM, Israel, June 07, 2021 (GLOBE NEWSWIRE) -- BrainsWay Ltd . (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation tr...

3 months ago - GlobeNewsWire

BrainsWay (BWAY) is in Overbought Territory: What's Next?

BrainsWay (BWAY) has moved higher as of late, but there could definitely be trouble on the horizon for this company

3 months ago - Zacks Investment Research

Brainsway Ltd. Sponsored ADR (BWAY) Moves 10.6% Higher: Will This Strength Last?

Brainsway Ltd. Sponsored ADR (BWAY) saw its shares surge in the last session with trading volume being higher than average.

3 months ago - Zacks Investment Research

BrainsWay Announces First of its Kind Positive Coverage Policy by Centene for the Treatment of OCD Utilizing Deep TMS™

CRESSKILL, N.J. and JERUSALEM, May 24, 2021 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments f...

3 months ago - GlobeNewsWire

BrainsWay Reports First Quarter 2021 Financial Results and Operational Highlights

Strong Revenue Growth of 47% Year-over-Year in Q1 2021

3 months ago - GlobeNewsWire

BrainsWay to Present at the Oppenheimer MedTech, Tools & Diagnostics Summit

CRESSKILL, N.J. and JERUSALEM, May 19, 2021 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in the advanced noninvasive treatment of brain disord...

3 months ago - GlobeNewsWire

Should You Buy BrainsWay (BWAY) Ahead of Earnings?

BrainsWay (BWAY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

4 months ago - Zacks Investment Research

BrainsWay to Report First Quarter 2021 Financial Results on May 20, 2021

CRESSKILL, N.J. and JERUSALEM, Israel, May 06, 2021 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in the advanced noninvasive treatment of brai...

4 months ago - GlobeNewsWire

BrainsWay Announces Appointment of R. Scott Areglado as Senior Vice President and Chief Financial Officer

CRESSKILL, N.J. and JERUSALEM, May 05, 2021 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments f...

4 months ago - GlobeNewsWire

BrainsWay Announces Social Media Sweepstakes to Celebrate Mental Health Awareness Month

The Sweepstakes, demonstrating how Deep Transcranial Magnetic Stimulation (Deep TMS) can fit into an average day, offers participants a chance to be one of 20 winners who will receive a curated self-car...

4 months ago - GlobeNewsWire

BrainsWay Announces Launch of Noninvasive Treatment for Smoking Addiction to U.S. Providers

Patients in areas across the country now have access to Deep Transcranial Magnetic Stimulation (Deep TMS) therapy as an aid for short-term smoking cessation Patients in areas across the country now have...

4 months ago - GlobeNewsWire

Strength Seen in Brainsway Ltd. Sponsored ADR (BWAY): Can Its 7.3% Jump Turn into More Strength?

Brainsway Ltd. Sponsored ADR (BWAY) witnessed a jump in share price last session on above-average trading volume.

4 months ago - Zacks Investment Research

BrainsWay Stock Is Trading Higher After FDA OK's Three-Minute Theta Burst Treatment Protocol For Major Depressive Dis...

The FDA has granted 501(k) clearance for BrainsWay Ltd's (NASDAQ: BWAY) Theta Burst three-minute protocol utilizing its Deep Transcranial Magnetic Stimulation (Deep TMS) system for major depressive diso...

4 months ago - Benzinga

BrainsWay Receives FDA Clearance for Three-Minute Theta Burst Treatment Protocol for Major Depressive Disorder

Shorter Protocol Further Expands Access to Care Shorter Protocol Further Expands Access to Care

4 months ago - GlobeNewsWire

BrainsWay Announces 100,000 Patients Treated with Deep Transcranial Magnetic Stimulation (Deep TMS)

The FDA cleared technology is a noninvasive treatment for depression, OCD, and smoking addiction The FDA cleared technology is a noninvasive treatment for depression, OCD, and smoking addiction

5 months ago - GlobeNewsWire

BrainsWay Reports Fourth Quarter and Full-Year 2020 Financial Results and Operational Highlights

Conference call to be held tomorrow, March 25, 2021, at 8:30 AM ET Conference call to be held tomorrow, March 25, 2021, at 8:30 AM ET

5 months ago - GlobeNewsWire

BrainsWay to Report Fourth Quarter and Full Year 2020 Financial Results on March 25, 2021

CRESSKILL, N.J., March 11, 2021 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in the advanced noninvasive treatment of brain disorders, today a...

6 months ago - GlobeNewsWire